Published in Vaccine on January 01, 1994
Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol (1995) 2.97
Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J Virol (1996) 2.75
Use of recombinant envelope proteins for serological diagnosis of Dengue virus infection in an immunochromatographic assay. Clin Diagn Lab Immunol (2001) 2.09
Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol (2000) 1.81
Flavivirus capsid is a dimeric alpha-helical protein. J Virol (2003) 1.43
PrM- and cell-binding domains of the dengue virus E protein. J Virol (1999) 1.27
The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine (2011) 1.26
Production and characterization of vaccines based on flaviviruses defective in replication. Virology (2006) 1.24
Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J Virol (1998) 1.23
Two distinct size classes of immature and mature subviral particles from tick-borne encephalitis virus. J Virol (2003) 1.17
Efficient assembly and secretion of recombinant subviral particles of the four dengue serotypes using native prM and E proteins. PLoS One (2009) 1.13
Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol (2003) 1.01
Structural analysis of viral nucleocapsids by subtraction of partial projections. J Struct Biol (2006) 0.98
An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol (2007) 0.95
Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin Vaccine Immunol (2007) 0.88
Expression of dengue-3 premembrane and envelope polyprotein in lettuce chloroplasts. Plant Mol Biol (2011) 0.86
Expression of particulate-form of Japanese encephalitis virus envelope protein in a stably transfected Drosophila cell line. Virol J (2007) 0.84
Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis. Bioconjug Chem (2010) 0.83
Molecular mechanism of pathogenesis of dengue virus: Entry and fusion with target cell. Indian J Clin Biochem (2005) 0.81
Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology (2016) 0.80
Passive protection assay of monoclonal antibodies against dengue virus in suckling mice. Curr Microbiol (2009) 0.78
Multi-walled carbon nanotubes increase antibody-producing B cells in mice immunized with a tetravalent vaccine candidate for dengue virus. J Nanobiotechnology (2016) 0.76
Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum (1977) 9.14
SWINE INFLUENZA : II. A HEMOPHILIC BACILLUS FROM THE RESPIRATORY TRACT OF INFECTED SWINE. J Exp Med (1931) 9.13
NEUTRALIZATION TESTS WITH SERA OF CONVALESCENT OR IMMUNIZED ANIMALS AND THE VIRUSES OF SWINE AND HUMAN INFLUENZA. J Exp Med (1936) 8.25
The complete DNA sequence of vaccinia virus. Virology (1990) 7.76
Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol (1989) 7.06
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
RNA polymerase activity in purified infectious vaccinia virus. Proc Natl Acad Sci U S A (1967) 5.49
Neurologic abnormalities of Lyme disease. Medicine (Baltimore) (1979) 3.98
THE ETIOLOGY OF SWINE INFLUENZA. Science (1931) 3.88
AN INTERMEDIATE HOST FOR THE SWINE INFLUENZA VIRUS. Science (1939) 3.87
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem (1975) 3.66
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
Electrophoresis of thymidine kinase activity synthesized by cells transformed by herpes simplex virus. Virology (1972) 3.05
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
"MAD ITCH" OF CATTLE. Science (1930) 2.90
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol (1995) 2.66
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology (1991) 2.63
Two African viruses serologically and morphologically related to rabies virus. J Virol (1970) 2.62
Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol (2001) 2.59
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol (1995) 2.55
Randomness and degrees of irregularity. Proc Natl Acad Sci U S A (1996) 2.55
Bunyaviridae. Intervirology (1980) 2.53
Thottapalayam virus: a presumptive arbovirus isolated from a shrew in India. Indian J Med Res (1971) 2.52
Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol (1997) 2.51
Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol (1993) 2.50
Oligonucleotide fingerprints of RNA species obtained from rhabdoviruses belonging to the vesicular stomatitis virus subgroup. J Virol (1977) 2.35
Nucleotide phosphohydrolase in purified vaccinia virus. J Virol (1968) 2.35
PSEUDORABIES AS A CONTAGIOUS DISEASE IN SWINE. Science (1934) 2.27
Increased proportion of complement-receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia. Blood (1972) 2.25
Protein kinase and specific phosphate acceptor proteins associated with vaccinia virus cores. J Virol (1972) 2.22
Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus. Proc Natl Acad Sci U S A (1975) 2.10
Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 2.09
The importance of inorganic phosphate in regulation of energy metabolism of Streptococcus lactis. J Biol Chem (1981) 2.05
Vaccinia virus host range genes. Virology (1990) 2.02
Detection of antibodies to alphaviruses by enzyme-linked immunosorbent assay. J Clin Microbiol (1979) 2.01
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med (1995) 1.99
Proposed antigenic classification of registered arboviruses I. Togaviridae, Alphavirus. Intervirology (1980) 1.98
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
A Study of Air Pollution in New York City. Am J Public Health Nations Health (1937) 1.98
Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J Virol (1993) 1.97
An update on the vaccinia virus genome. Virology (1993) 1.95
Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol (1999) 1.94
Venezuelan haemorrhagic fever. Lancet (1991) 1.90
Formation of recombinants between snowshoe hare and La Crosse bunyaviruses. J Virol (1977) 1.87
Epidemiological aspects of the 1969 yellow fever epidemic in Nigeria. Bull World Health Organ (1972) 1.86
Not all (possibly) "random" sequences are created equal. Proc Natl Acad Sci U S A (1997) 1.85
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol (1989) 1.84
Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. J Virol (1998) 1.83
Genetic and antigenic diversity among eastern equine encephalitis viruses from North, Central, and South America. Am J Trop Med Hyg (1999) 1.83
TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci U S A (1994) 1.80
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78
THE ANTIBODY RESPONSE TO SWINE INFLUENZA. J Exp Med (1939) 1.77
Polyadenylate polymerase from vaccinia virions. Nat New Biol (1973) 1.76
Two nucleic acid-dependent nucleoside triphosphate phosphohydrolases from vaccinia virus. Nucleotide substrate and polynucleotide cofactor specificities. J Biol Chem (1974) 1.76
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Nucleotide sequences and phylogeny of the nucleocapsid gene of Oropouche virus. J Gen Virol (2000) 1.70
Electron microscopic and antigenic studies of uncharacterized viruses. II. Evidence suggesting the placement of viruses in the family Bunyaviridae. Arch Virol (1989) 1.67
Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine (1991) 1.66
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
An antiviral substance from Penicillium funiculosum. V. Induction of interferon by helenine. J Exp Med (1966) 1.63
Detection of La Crosse arbovirus antigen in mosquito pools: application of chromogenic and fluorogenic enzyme immunoassay systems. J Clin Microbiol (1982) 1.62
The foot-and-mouth disease virus leader proteinase gene is not required for viral replication. J Virol (1995) 1.61
A CHANGE IN RABBIT FIBROMA VIRUS SUGGESTING MUTATION : III. INTERPRETATION OF FINDINGS. J Exp Med (1936) 1.61
Recombinant vaccinia virus: immunization against multiple pathogens. Science (1985) 1.60
Metabolism of monofluoro- and monochlorobenzoates by a dentrifying bacterium. Arch Microbiol (1979) 1.58
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56
Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine (1988) 1.55
Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55
Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa. Virology (1996) 1.53
Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes (1996) 1.53
Transcriptional complexity of vaccinia virus in vivo and in vitro. J Virol (1977) 1.53
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst (1997) 1.52
Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology (1992) 1.48
Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J Infect Dis (1995) 1.46
High molecular weight virion-associated RNA of vaccinia. A possible precursor to 8 to 12 S mRNA. J Biol Chem (1977) 1.45
Characterization of the effect of aphidicolin on adenovirus DNA replication: evidence in support of a protein primer model of initiation. Nucleic Acids Res (1981) 1.45
Genetic determinants of altered virulence of Taiwanese foot-and-mouth disease virus. J Virol (2000) 1.44
Recurrence of Rift Valley fever in Egypt. Lancet (1993) 1.44
Identification of the active-site residues of the L proteinase of foot-and-mouth disease virus. J Virol (1995) 1.42
An antiviral substance from Penicillium funiculosum. IV. Inquiry into the mechanism by which helenine exerts its antiviral effect. J Exp Med (1966) 1.40
Attenuation of virulence of a bunyavirus involving an L RNA defect and isolation of LAC/SSH/LAC and LAC/SSH/SSH reassortants. Virology (1981) 1.39
Partial nucleotide sequence of the Japanese encephalitis virus genome. Virology (1987) 1.39
Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. J Interferon Cytokine Res (1998) 1.38
Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses. Virology (1995) 1.36